M. Hussain Et Al. , "Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)," CLINICAL CANCER RESEARCH , vol.28, no.8, pp.1518-1530, 2022
Hussain, M. Et Al. 2022. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). CLINICAL CANCER RESEARCH , vol.28, no.8 , 1518-1530.
Hussain, M., Corcoran, C., Sibilla, C., Fizazi, K., Saad, F., Shore, N., ... Sandhu, S.(2022). Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). CLINICAL CANCER RESEARCH , vol.28, no.8, 1518-1530.
Hussain, Maha Et Al. "Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)," CLINICAL CANCER RESEARCH , vol.28, no.8, 1518-1530, 2022
Hussain, Maha Et Al. "Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)." CLINICAL CANCER RESEARCH , vol.28, no.8, pp.1518-1530, 2022
Hussain, M. Et Al. (2022) . "Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)." CLINICAL CANCER RESEARCH , vol.28, no.8, pp.1518-1530.
@article{article, author={Maha Hussain Et Al. }, title={Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)}, journal={CLINICAL CANCER RESEARCH}, year=2022, pages={1518-1530} }